Su carrito
DR. SCOTT TUNIS HAS RETIRED, EFFECTIVE MARCH 2023. YOUR MEDICAL RECORDS HAVE BEEN TRANSFERRED TO WILMINGTON EYE: (910) 763-3601. DR. SCOTT TUNIS HAS RETIRED, EFFECTIVE MARCH 2023. YOUR MEDICAL RECORDS HAVE BEEN TRANSFERRED TO WILMINGTON EYE: (910) 763-3601.

About Dr. Scott Tunis

 

Scott W. Tunis MD FACS is a Board Certified Ophthalmologist and a Fellow of the American College of Surgeons. He specializes in LASIK and laser vision correction procedures and is a recognized specialist in cataract surgery and corneal disease. He holds two United States Patents in intraocular lens implant technology and was involved in the FDA studies for myopic LASIK.

CREDENTIALS

  • Amherst College BA 1977
  • University of Virginia School of Medicine MD 1981
  • Medical University of South Carolina Residency in Ophthalmology 1985
  • Board Certified, American Board of Ophthalmology 1987
  • Fellow, American Academy of Ophthalmology
  • Fellow, American College of Surgeons
  • Member, American Society of Cataract and Refractive Surgery
  • Consumer’s Research Council, America’s Top Ophthalmologists
  • 2010 PS250 Premier Surgeon – one of the 250 Top Innovators in Premium IOL Surgery
  • 2016 PS300 Premier Surgeon – one of the 300 Top Innovators in Premium IOL Surgery

PRACTICE EXPERIENCE

  • One of the Carolinas’ most experienced LASIK Surgeons with over 25 years LASIK experience and more than 30,000 LASIK procedures performed since 1994
  • Over 38 years Cataract surgery experience with more than 30,000 Cataract procedures performed
  • Holder of two United States Patents in Intraocular Lens Implant Technology: US Patents 5549614 and 5556400
  • Past Chief of Ophthalmology, Holy Cross Hospital, Fort Lauderdale, FL
  • Past Chief of Ophthalmology, New Hanover Regional Medical Center, Wilmington, NC
  • Founder and Medical DirectorSpare-Specs, LLC
  • President, Founder and Medical Director: Runners Essential Vitamin, LLC
  • President, Founder and Medical Director: ImmunoEssentials100
  • Principal Investigator, “The Post-Vitrectomy Lenstatin Study”: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy : ClinicalTrials.gov Identifier NCT02131194